rezpegaldesleukin

Nektar Therapeutics faces securities fraud lawsuit over failed alopecia trial and alleged protocol disclosure violations. Stock fell 7.8% on December 16, 2025.

Pomerantz LLP filed class action against $NKTR over REZOLVE-AA trial failure. Stock dropped 7.77% after December disclosure of ineligible patient enrollment issues.

Nektar Therapeutics surges 18% after reporting positive phase 2b results for rezpegaldesleukin, an investigational alopecia areata treatment, advancing into later-stage trials.

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.

Nektar Therapeutics faces class action lawsuit alleging securities fraud over alleged REZOLVE-AA trial misstatements involving improper patient enrollment procedures.

Robbins LLP files class action against Nektar Therapeutics for allegedly concealing REZOLVE-AA trial protocol violations, triggering 7.77% stock decline after trial failure announcement.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.

Nektar Therapeutics ($NKTR) faces class action lawsuit alleging false statements about REZOLVE-AA trial protocol adherence, threatening regulatory approval timelines and shareholder value.

Schall Law Firm seeks investors in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment and integrity.